Financial Performance - Liquidia Corporation reported a second-quarter loss of $0.49, missing the consensus estimate of a loss of $0.43 [1] - Sales reached $8.84 million, significantly exceeding the consensus of $3.86 million [1] - The net product revenue for the three months ending June 30, 2025, was $6.5 million, following the full FDA approval for Yutrepia on May 23, 2025 [1] Product Development and Clinical Trials - The company analyzed interim data from the ASCENT study, which enrolled 54 patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) [3] - The tolerability profile of Yutrepia in PH-ILD was consistent with initial observations, with 18.5% of patients discontinuing the study, none due to drug-related adverse events [4] - The median improvements in six-minute walk distance were 21.5 meters at week 8 and 31.5 meters at week 16, indicating positive efficacy [5] Market Reaction - LQDA stock increased by 14.13%, reaching $24.20 at the time of publication [6]